- Kombinoitaessa sorafenib ja celecoxib ne synergisesti estävät tuumorikasvua ja non-small cell- tyyppisen keuhkosyöpäsolun (NSCLC) kasvua in vitro sekä in vivo (keho-oloissa).
- Sorafenib (SOR) on VEGFR estäjä. proteiinikinaasiestäjiin kuuluva lääke kuten Nexavar L01X E05.
- Celecoxib (CXB) kuten Celebra, M01A H01, on COX-2 estäjä. Se on non- steroidinen anti-inflammatorinen antireumalääke)
In the present study, we selected sorafenib (SOR), a VEGFR inhibitor, in combination with celecoxib (CXB), a COX-2 inhibitor, for suppressing tumor growth and simultaneously for reducing doses of both drugs for the treatment of NSCLC
...the results also showed that the combination of SOR and CXB significantly increased the induction of apoptosis and decreased the expression of inhibitor of apoptosis genes, survivin and Bcl-2....
... the combination treatment significantly suppressed constitutive phosphorylation of MEK and ERK, which may contribute to the inhibition of tumor growth. Taken together, our findings revealed that this additive combination of SOR and CXB is a potential drug candidate for the treatment of NSCLC...
Päivitys 18.4. 2014
Inga kommentarer:
Skicka en kommentar